Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer

Gou Kaneko, Eiji Kikuchi, Kazuhiro Matsumoto, Jun Obata, So Nakamura, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: Downstaging by neoadjuvant chemotherapy improves the survival of patients with muscle-invasive bladder cancer. In salvage setting, gemcitabine plus cisplatin has demonstrated an efficacy similar to that of methotrexate, vinblastine, doxorubicin and cisplatin with less toxicity. Therefore, the application of neoadjuvant gemcitabine plus cisplatin is also being anticipated. Methods: Twenty-two patients who received neoadjuvant gemcitabine plus cisplatin were evaluated. The rate of downstaging, chemotherapy delivery profile and toxicity data were assessed. As comparator group, nine patients who were administered with neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin were evaluated. Results: A mean of 1.9 cycles of neoadjuvant gemcitabine plus cisplatin were performed. Achieved drug intensity for gemcitabine and cisplatin was 83.8 and 95.4%. Downstaging to pT0 and <pT2 was achieved in 50.0 and 63.6%. Grade 3 or 4 neutropenia, anemia, thrombocytopenia and febrile neutropenia appeared in 14.3, 2.4, 21.4 and 2.4%, respectively. Grade 3 or 4 non-hematologic toxicity was not observed. Thrombocytosis developed in 26.2%. A mean of 2.3 cycles of neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin were performed. The achieved drug intensities for methotrexate, vinblastine, doxorubicin and cisplatin were 59.6, 69.8, 100 and 88.6%. In patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin, downstaging to pT0 and <pT2 was achieved in 22.2 and 44.4%. Grade 3 or 4 neutropenia, anemia and thrombocytopenia was present in 19.1, 9.5 and 4.8%. Grade 3 nausea developed in 28.6%. Conclusions: The rate of downstaging by neoadjuvant gemcitabine plus cisplatin was comparable with that by methotrexate, vinblastine, doxorubicin and cisplatin. Gemcitabine plus cisplatin was associated with less non-hematologic toxicity than methotrexate, vinblastine, doxorubicin and cisplatin.

Original languageEnglish
Article numberhyr068
Pages (from-to)908-914
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number7
DOIs
Publication statusPublished - 2011 Jul

Fingerprint

gemcitabine
Urinary Bladder Neoplasms
Cisplatin
Muscles
Vinblastine
Methotrexate
Doxorubicin
Neutropenia
Thrombocytopenia
Anemia

Keywords

  • Bladder cancer
  • Cisplatin
  • Gemcitabine
  • Neoadjuvant chemotherapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. / Kaneko, Gou; Kikuchi, Eiji; Matsumoto, Kazuhiro; Obata, Jun; Nakamura, So; Miyajima, Akira; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 7, hyr068, 07.2011, p. 908-914.

Research output: Contribution to journalArticle

Kaneko, Gou ; Kikuchi, Eiji ; Matsumoto, Kazuhiro ; Obata, Jun ; Nakamura, So ; Miyajima, Akira ; Oya, Mototsugu. / Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. In: Japanese Journal of Clinical Oncology. 2011 ; Vol. 41, No. 7. pp. 908-914.
@article{b4db753dbead4411913145bf6a3b9582,
title = "Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer",
abstract = "Objective: Downstaging by neoadjuvant chemotherapy improves the survival of patients with muscle-invasive bladder cancer. In salvage setting, gemcitabine plus cisplatin has demonstrated an efficacy similar to that of methotrexate, vinblastine, doxorubicin and cisplatin with less toxicity. Therefore, the application of neoadjuvant gemcitabine plus cisplatin is also being anticipated. Methods: Twenty-two patients who received neoadjuvant gemcitabine plus cisplatin were evaluated. The rate of downstaging, chemotherapy delivery profile and toxicity data were assessed. As comparator group, nine patients who were administered with neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin were evaluated. Results: A mean of 1.9 cycles of neoadjuvant gemcitabine plus cisplatin were performed. Achieved drug intensity for gemcitabine and cisplatin was 83.8 and 95.4{\%}. Downstaging to pT0 and",
keywords = "Bladder cancer, Cisplatin, Gemcitabine, Neoadjuvant chemotherapy, Toxicity",
author = "Gou Kaneko and Eiji Kikuchi and Kazuhiro Matsumoto and Jun Obata and So Nakamura and Akira Miyajima and Mototsugu Oya",
year = "2011",
month = "7",
doi = "10.1093/jjco/hyr068",
language = "English",
volume = "41",
pages = "908--914",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer

AU - Kaneko, Gou

AU - Kikuchi, Eiji

AU - Matsumoto, Kazuhiro

AU - Obata, Jun

AU - Nakamura, So

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2011/7

Y1 - 2011/7

N2 - Objective: Downstaging by neoadjuvant chemotherapy improves the survival of patients with muscle-invasive bladder cancer. In salvage setting, gemcitabine plus cisplatin has demonstrated an efficacy similar to that of methotrexate, vinblastine, doxorubicin and cisplatin with less toxicity. Therefore, the application of neoadjuvant gemcitabine plus cisplatin is also being anticipated. Methods: Twenty-two patients who received neoadjuvant gemcitabine plus cisplatin were evaluated. The rate of downstaging, chemotherapy delivery profile and toxicity data were assessed. As comparator group, nine patients who were administered with neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin were evaluated. Results: A mean of 1.9 cycles of neoadjuvant gemcitabine plus cisplatin were performed. Achieved drug intensity for gemcitabine and cisplatin was 83.8 and 95.4%. Downstaging to pT0 and

AB - Objective: Downstaging by neoadjuvant chemotherapy improves the survival of patients with muscle-invasive bladder cancer. In salvage setting, gemcitabine plus cisplatin has demonstrated an efficacy similar to that of methotrexate, vinblastine, doxorubicin and cisplatin with less toxicity. Therefore, the application of neoadjuvant gemcitabine plus cisplatin is also being anticipated. Methods: Twenty-two patients who received neoadjuvant gemcitabine plus cisplatin were evaluated. The rate of downstaging, chemotherapy delivery profile and toxicity data were assessed. As comparator group, nine patients who were administered with neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin were evaluated. Results: A mean of 1.9 cycles of neoadjuvant gemcitabine plus cisplatin were performed. Achieved drug intensity for gemcitabine and cisplatin was 83.8 and 95.4%. Downstaging to pT0 and

KW - Bladder cancer

KW - Cisplatin

KW - Gemcitabine

KW - Neoadjuvant chemotherapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=79960050144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960050144&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyr068

DO - 10.1093/jjco/hyr068

M3 - Article

VL - 41

SP - 908

EP - 914

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

M1 - hyr068

ER -